Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/21929
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2021-09-14T08:25:49Z-
dc.date.available2021-09-14T08:25:49Z-
dc.date.issued2006-
dc.identifier.citationKılıç, N. vd. (2006). ''Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability''. International Journal of Urology, 13(2), 105-108.en_US
dc.identifier.issn0919-8172-
dc.identifier.issn1442-2042-
dc.identifier.urihttps://doi.org/10.1111/j.1442-2042.2006.01240.x-
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/j.1442-2042.2006.01240.x-
dc.identifier.urihttp://hdl.handle.net/11452/21929-
dc.description.abstractBackground: Treatment with anticholinergic agents is the mainstay of therapy for detrusor instability (DI), a chronic and morbid condition characterized by urge urinary incontinence. The aim of this study is to assess the effectiveness and tolerability of tolterodine and oxybutynin in children with DI. Methods: A total of 60 children with DI were enrolled, 30 (14 male, 16 female, mean age 7.97 +/- 2.71 years) in the tolterodine group and 30 (12 male, 18 female, mean age 7.33 +/- 2.23 years) in the oxybutynin group. In this prospective study we reviewed data from 60 children followed for at least 6 months. All of the patients in the study population had a history of dysfunctional voiding. Urodynamic investigations were conducted in all of the patients before and after anticholinergic treatment. Episodes of urge urinary incontinence and adverse events were also evaluated. Results: Improvements in urge incontinence episodes were similar for the children who received tolterodine or oxybutynin. Improvements in the urodynamic parameters were also the same in the two groups. Adverse events were significantly lower in the tolterodine group (13 events in 13 patients) compared to the oxybutynin group (27 events in 20 patients; P = 0.027). Conclusion: Reductions in urge urinary incontinence episodes were similar with tolterodine and oxybutynin in children with DI. Side-effects were more common with oxybutynin. Treatment of children with DI with tolterodine shows significantly better tolerability and this may enhance children's compliance during long-term treatment.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectUrology & nephrologyen_US
dc.subjectTolterodineen_US
dc.subjectOxybutyninen_US
dc.subjectDetrusor instabilityen_US
dc.subjectAnticholinergicsen_US
dc.subjectDrugen_US
dc.subjectChlorideen_US
dc.subjectTolerabilityen_US
dc.subjectEfficacyen_US
dc.subjectUrinary-incontinenceen_US
dc.subjectOveractive bladderen_US
dc.titleComparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instabilityen_US
dc.typeArticleen_US
dc.identifier.wos000235843500002tr_TR
dc.identifier.scopus2-s2.0-33644839907tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Cerrahisi Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Ürolojisi ve Biyoistatistik Anabilim Dalı.tr_TR
dc.identifier.startpage105tr_TR
dc.identifier.endpage108tr_TR
dc.identifier.volume13tr_TR
dc.identifier.issue2tr_TR
dc.relation.journalInternational Journal of Urologyen_US
dc.contributor.buuauthorKılıç, Nizamettin-
dc.contributor.buuauthorBalkan, Emin-
dc.contributor.buuauthorAkgöz, Semra-
dc.contributor.buuauthorŞen, Nuri-
dc.contributor.buuauthorDoğruyol, Hasan-
dc.contributor.researcheridAAI-3656-2021tr_TR
dc.identifier.pubmed16563131tr_TR
dc.subject.wosUrology & nephrologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubmeden_US
dc.wos.quartileQ4en_US
dc.subject.scopusNocturnal Enuresis; Deamino Arginine Vasopressin; Overactive Bladderen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.